In a report released today, Jonathan Chang from SVB Securities maintained a Hold rating on ImmunoGen (IMGN – Research Report), with a price target of $4.00. The company's shares closed last Friday at $4.54. According to TipRanks.com, Chang is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -19.6% and a 19.6% success rate. Chang covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Karyopharm Therapeutics, and Mersana Therapeutics. ImmunoGen has an analyst consensus of Moderate Buy, with a price target consensus of $11.50. See the top stocks recommended by analysts >> ImmunoGen's market cap is currently $1.
https://www.tipranks.com/news/blurbs/svb-securities-keeps-their-hold-rating-on-immunogen-imgn?utm_source=advfn.com&utm_medium=referral
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Nov 2022 to Dec 2022 Click Here for more ImmunoGen Charts.
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Dec 2021 to Dec 2022 Click Here for more ImmunoGen Charts.